These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Effect of the acetylosalicyd acid (ASA) and ticlopidine therapy on clinical condition and parameters of blood platelets in patients with peripheral arterial occlusive disease (PAOD)].
    Author: Leo W, Westrych R, Bissinger A, Okraszewski J, Baj Z.
    Journal: Pol Merkur Lekarski; 2007 Nov; 23(137):335-9. PubMed ID: 18361314.
    Abstract:
    UNLABELLED: Hyperreactivity of platelets is one of the agents promoting atherosclerosis and its organ complications THE AIM: To assess antiplatelet therapy with acetylsalicylic acid (ASA) and ticlopidine on clinical condition and chosen parameters of blood platelet activity and reactivity in patients with PAOD. MATERIAL AND METHODS: Twenty eight patients, aged 40-65 years, were enrolled to the study after clinically and echographically established diagnosis. The patients were randomly divided into two groups: 13 were treated with ASA 300 mg daily and 15 with ticlopidine 2 x 250 mg daily. The therapy lasted two months. Clinical stress tests were done on moving track according to thB modified Bruce's protocol and blood platelets activity parameters on flow-cytometer. Percentage of spontaneous platelet aggregates, microplatelets and platelets expressing CD62P, Cd42b and CD41 were tested. RESULTS: Supplementation therapy with ASA or ticlopidine to the standard therapy with pentoxyphylline resulted in a marked increase in the distance of claudication evaluated subjectively and objectively on moving track and revealed silent myocardial ischemia in 4 PAOD patients. In platelet activation tests, both at rest and after the stress test, independently of the antiplatelet agent used, we observed significant drop in the percentage of platelet aggregates and symptoms of vWF receptor activation. No effect of the therapy on CD62P expression, reflecting platelet release reaction and CD41 expression (the fragment of receptor for fibrynogen) were noted. CONCLUSIONS: Both antiplatelet drugs have beneficial effect on clinical condition of PAOD patients and the effect may results from their anti-aggregative and anti-adhesive properties.
    [Abstract] [Full Text] [Related] [New Search]